

16 October 2024

## Dermatology Medicines

I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question?

How many patients were treated in September 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) 7
- Baricitinib (Olmiant) <5
- Dupilumab (Dupixent) 194
- Lebrikizumab (Ebglyss) 5
- Omalizumab (Xolair) 34
- Tralokinumab (Adtralza) <5
- Upadacitinib (Rinvoq) 36

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.